Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.

about

The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies.Clinical guidance for radioiodine refractory differentiated thyroid cancer.Refractory thyroid carcinoma: which systemic treatment to use?

P2860

Q38865611-8EC8A996-93F9-4539-9DC3-CCEFDA863CE3 Q47863818-2E7DCA52-6C94-49E4-8BF7-CA700EDFE921 Q49335901-DDB346CE-62B2-4E5E-95ED-E0A8C6769093

P2860

Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.

Item

http://www.wikidata.org/entity/Q38823954

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.

@en

type

Item

label

Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.

@en

prefLabel

Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.

@en

P1476

Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.

@en

P2093

A Dimitrios Colevas

http://www.w3.org/2001/XMLSchema#string

Sujata Narayanan

http://www.w3.org/2001/XMLSchema#string

P2860

Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer

Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis

Progress in molecular-based management of differentiated thyroid cancer

RAS mutations in thyroid cancer

RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort.

PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]

P2888

s11864-016-0404-6

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S11864-016-0404-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1008817262

http://www.w3.org/2001/XMLSchema#string

P698

27139457

http://www.w3.org/2001/XMLSchema#string

Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.

about

P2860

P2860

Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698